Crescent Biopharma, Inc.
CBIO
$12.94
-$0.16-1.22%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 8.95M | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 21.03M | ||||
| Operating Income | -21.03M | ||||
| Income Before Tax | -21.79M | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -21.79M | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -21.79M | ||||
| EBIT | -21.03M | ||||
| EBITDA | -21.03M | ||||
| EPS Basic | -1.11 | ||||
| Normalized Basic EPS | -0.70 | ||||
| EPS Diluted | -1.11 | ||||
| Normalized Diluted EPS | -0.70 | ||||
| Average Basic Shares Outstanding | 19.55M | ||||
| Average Diluted Shares Outstanding | 19.55M | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||